|
5 mg (N=6) |
5 mg (N=6) |
15 mg (N=6) |
15 mg (N=6) |
40 mg (N=6) |
40 mg (N=6) |
80 mg (N=6) |
80 mg (N=6) |
120 mg (N=5) |
120 mg (N=5) |
160 mg (N=1) |
160 mg (N=1) |
Placebo (N=12) |
Placebo (N=12) |
|
n (%) |
m |
n (%) |
m |
n (%) |
m |
n (%) |
m |
n
(%) |
m |
n (%) |
m |
n (%) |
m |
Infections and infestations |
3 (50.0%) |
3 |
1 (16.7%) |
1 |
1 (16.7%) |
1 |
1 (16.7%) |
1 |
1 (20.0%) |
1 |
0 |
0 |
2 (16.7%) |
2 |
Nasopharyngitis |
3 (50.0%) |
3 |
1 (16.7%) |
1 |
1 (16.7%) |
1 |
1
(16.7%) |
1 |
1 (20.0%) |
1 |
0 |
0 |
2 (16.7%) |
2 |
Nervous system disorders |
1 (16.7%) |
1 |
2 (33.3%) |
2 |
0 |
0 |
1 (16.7%) |
1 |
1 (20.0%) |
2 |
1 (100%) |
3 |
2 (16.7%) |
2 |
Headache |
1 (16.7%) |
1 |
2 (33.3%) |
2 |
0 |
0 |
1 (16.7%) |
1 |
1 (20.0%) |
1 |
0 |
0 |
2 (16.7%) |
2 |
Disturbance in attention |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (20.0%) |
1 |
1 (100%) |
1 |
0 |
0 |
Dizziness |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (100%) |
1 |
0 |
0 |
Tremor |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (100%) |
1 |
0 |
0 |
Gastrointestinal disorders |
0 |
0 |
2 (33.3%) |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
1 |
Gastrointestinal hypermotility |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Toothache |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
1 |
Vomiting |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Psychiatric disorders |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
(20.0%) |
1 |
1 (100%) |
2 |
0 |
0 |
Restlessness |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (20.0%) |
1 |
1
(100%) |
1 |
0 |
0 |
Nervousness |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (100%) |
1 |
0 |
0 |
Respiratory, thoracic and mediastinal disorders |
1 (16.7%) |
1 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
2 |
Oropharyngeal pain |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
1 |
Cough |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
1 |
Epistaxis |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Skin and subcutaneous tissue disorders |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (100%) |
1 |
0 |
0 |
Cold sweat |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (100%) |
1 |
0 |
0 |
Eczema |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Metabolism and nutrition disorders |
0 |
0 |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Decreased appetite |
0 |
0 |
0 |
0 |
1 (16.7%) |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Musculoskeletal and connective tissue disorders |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
1 |
Back pain |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (8.3%) |
1 |